These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 20482531)
21. Tumor antigens as surrogate markers and targets for therapy and vaccines. Dalgleish A; Pandha H Adv Cancer Res; 2007; 96():175-90. PubMed ID: 17161680 [TBL] [Abstract][Full Text] [Related]
22. Immunizing against breast cancer: a new swing for an old sword. Curigliano G; Locatelli M; Fumagalli L; Goldhirsch A Breast; 2009 Oct; 18 Suppl 3():S51-4. PubMed ID: 19914543 [TBL] [Abstract][Full Text] [Related]
23. Novel approaches to therapeutic cancer vaccines. Hellstrom KE; Hellstrom I Expert Rev Vaccines; 2003 Aug; 2(4):517-32. PubMed ID: 14711336 [TBL] [Abstract][Full Text] [Related]
24. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Seremet T; Brasseur F; Coulie PG Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282 [TBL] [Abstract][Full Text] [Related]
25. Cancer vaccines: a critical review on clinical impact. Bitton RJ Curr Opin Mol Ther; 2004 Feb; 6(1):17-26. PubMed ID: 15011777 [TBL] [Abstract][Full Text] [Related]
28. Therapeutic cancer vaccines: using unique antigens. Lewis JJ Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14653-6. PubMed ID: 15297620 [TBL] [Abstract][Full Text] [Related]
29. Cancer vaccines and immunotherapies: emerging perspectives. Henderson RA; Mossman S; Nairn N; Cheever MA Vaccine; 2005 Mar; 23(17-18):2359-62. PubMed ID: 15755628 [TBL] [Abstract][Full Text] [Related]
30. Dendritic cells in cancer immunotherapy. Vulink A; Radford KJ; Melief C; Hart DN Adv Cancer Res; 2008; 99():363-407. PubMed ID: 18037410 [TBL] [Abstract][Full Text] [Related]
31. Tumor escape from the immune response: a major hurdle for successful immunotherapy of cancer? Chouaib S Tunis Med; 2005 Dec; 83 Suppl 12():7-10. PubMed ID: 16430055 [No Abstract] [Full Text] [Related]
32. Molecular pathological approaches to human tumor immunology. Sato N; Hirohashi Y; Tsukahara T; Kikuchi T; Sahara H; Kamiguchi K; Ichimiya S; Tamura Y; Torigoe T Pathol Int; 2009 Apr; 59(4):205-17. PubMed ID: 19351363 [TBL] [Abstract][Full Text] [Related]
33. Tumor-host immune interactions and dendritic cell dysfunction. Yang L; Carbone DP Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555 [TBL] [Abstract][Full Text] [Related]
34. [Cytotoxic T-lymphocytes and the recognition of tumor antigens--an approach to "preventive tumor vaccination?"]. Peiper M; Goedegebuure PS; Eberlein TJ; Zornig C Zentralbl Chir; 1997; 122(3):141-8. PubMed ID: 9206906 [TBL] [Abstract][Full Text] [Related]
35. Therapeutic cancer vaccines. Acres B; Paul S; Haegel-Kronenberger H; Calmels B; Squiban P Curr Opin Mol Ther; 2004 Feb; 6(1):40-7. PubMed ID: 15011780 [TBL] [Abstract][Full Text] [Related]
36. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer? Zöller M; Matzku S Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935 [TBL] [Abstract][Full Text] [Related]